Roche has signed a manufacturing contract with India-based Emcure Pharmaceuticals for its anti-cancer biologics Herceptin and MabThera, as reported by The Economic Times. Emcure will manufacture Herceptin and MabThera for the Indian market and based on the success, may be marketed in other developing countries. These drugs are currently under process development and are expected to be available by 2013.   “This deal will equip Emcure to manufacture products that are sophisticated monoclonal anti...